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Abstract
Background: The EORTC-QLQ-C30 is a widely used health related quality of life (HRQoL) questionnaire in lung
cancer patients. Small HRQoL treatment effects are often reported as mean differences (MDs) between treatments,
which are rarely justified or understood by patients and clinicians. An alternative approach using odds ratios (OR)
for reporting effects is proposed. This may offer advantages including facilitating alignment between patient and
clinician understanding of HRQoL effects.
Methods: Data from six CRUK sponsored randomized controlled lung cancer trials (2 small cell and 4 in non-small
cell, in 2909 patients) were used to HRQoL effects. Results from Beta-Binomial (BB) standard mixed effects were
compared. Preferences for ORs vs MDs were determined and Time to Deterioration (TD) was also compared.
Results: HRQoL effects using ORs offered coherent interpretations: MDs >0 resulted in ORs >1 and vice versa; effect
sizes were classified as ‘Trivial’ if the OR was between 1 ± 0.05 (i.e. 0.95 to 1.05); ‘Small’: for 1 ± 0.1; ‘Medium’: 1 ± 0.2
and ‘Large’: OR <0.8 or >1.20. Small HRQoL effects on the MD scale may translate to important treatment
differences on the OR scale: for example, a worsening in symptoms (MD) by 2.6 points (p = 0.1314) would be a
17 % deterioration (p < 0.0001) with an OR. Hence important differences may be missed with MD; conversely, small
ORs are unlikely to yield large MDs because methods based on OR model skewed data well. Initial evidence also
suggests oncologists prefer ORs over MDs since interpretation is similar to hazard ratios.
Conclusion: Reporting HRQoL benefits as MDs can be misleading. Estimates of HRQoL treatment effects in terms of
ORs are preferred over MDs. Future analysis of QLQ-C30 and other HRQoL measures should consider reporting
HRQoL treatment effects as ORs.
Keywords: EORTC-QLQ-C30, Lung cancer, Quality of life, Beta binomial, Treatment effect size, MD: Mean Differences,
ORs: Odds Ratios
Background
Health related quality of life (HRQoL) is an important
endpoint in cancer trials for several reasons. First, where
effect sizes are small, HRQoL can ‘add value’ to expen-
sive cancer treatments. Secondly, considerable time is
spent completing instruments for the purpose of esti-
mating the impact of treatments on HRQoL. Therefore,
such efforts should result in HRQoL effects that are
meaningful and interpretable, especially where HRQoL
is a primary or co-primary endpoint [1]. Thirdly, some
anti-cancer treatments exhibit serious side-effects, des-
pite improvements in overall survival (OS); HRQoL is
also reported to be a predictor of survival in lung cancer
patients [2], the leading cause of death among cancers
[3]. It would be important to understand for example,
how survival differs between patients with ‘poor’ baseline
HRQoL, compared to those with ‘Good’ HRQoL. Finally,
HRQoL outcomes are often required for cost-effectiveness
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analyses and drug reimbursement [4, 5]. Therefore,
understanding and interpreting HRQoL data is crucial
in evaluating cancer treatments.
The EORTC-QLQ-C30 (QLQ-C30) is a widely used
cancer specific instrument [6]. The instrument has 30
questions from which 15 domains (sub scales) are deter-
mined, consisting of 5 ‘function’ scales, 8 ‘symptom’
scales, a global quality of life (QL) scale and a finance
scale (FI). For QL and function domains, high scores in-
dicate better HRQoL. For symptom domains (and FI),
low scores indicate better HRQoL.
Treatment effects from the QLQ-C30 are often re-
ported as mean differences (MDs) [7], despite scores
having heavily skewed distributions with ceiling effects
(many patients with scores of 0 or 100) and censored
data due to progressive disease, death or failure to
complete questionnaires. The interpretation of HRQoL
MDs can be more complicated than survival endpoints.
Consequently, alternative measures of treatment effect
have been proposed.
Maringwa suggests a minimally important ‘difference
over time’ as a measure of effect [8]. The area under the
curve (AUC) can be difficult to interpret, although useful
for reducing multiple observations to a single value [9].
However, if HRQoL is measured at a few time points
(e.g. baseline and month 12), the AUC will have limited
value. Moreover, the interpretation of the effect can be-
come tricky (e.g. for HRQoL scores of 100 at each of 0, 1
and 2 months, the AUC score is but the original HRQoL
scale is 0 to 100).
Categorizing scores: e.g. improvements in symptoms
from ‘moderate’ or ‘severe’ (67–100 points at baseline) to
‘non’ or ‘little’ (0 to 33 points) was proposed by Langendjik
[10]. Reck and Norman [11, 12] suggested ‘noted’ changes
in HRQoL occur when a ‘shift’ of greater than half of the
baseline standard deviation is observed). Time to HRQoL
deterioration (TD) has been suggested (Anota) [13]. How-
ever different definitions of ‘deterioration’ lead to different
conclusions and median TD may not be estimable (e.g. few
events) and further complicated by non-proportional
hazards (PH). Interpretation of effects with TD using
HRs is however similar to ORs. Reporting a ‘Trend’ is
also a way of describing HRQoL over time (Schaake) [14],
although difficult to interpret (e.g. how much ‘more trend’
is there for experimental vs. control?).
The above measures of HRQoL effects can be difficult
to interpret for patients and clinicians. The mean is
often the statistic of choice to define treatment effect
sizes for HRQoL endpoints in most of these measures.
One commonly reported clinically relevant effect size
proposed by Osoba and King [6, 15, 16] is ≥10 points
MD (on any domain), a value used as a benchmark by
researchers to determine whether HRQoL benefits exist
[7]. Some researchers interpret a 10 point improvement
as a difference between treatments, while others as a 10
point change (improvement) from baseline (Hirsh) [6, 17],
which is not always possible. For example, if a patient
scores 8 points (or 92 points) at baseline, a reduction
(or increase) of 10 points is not possible. Moreover,
‘important’ treatment differences need not be the same for
symptom as functional scales. A worsening of 5 points in a
symptom scale may be more important than a 10 point
improvement in a functional scale.
For HRQoL endpoints, the magnitude of effect sizes
are often considered to be clinically relevant if a differ-
ence of 10 points is observed, regardless of whether
HRQoL is a primary or secondary outcome. Such re-
quirements are not expected of other secondary clinical
endpoints in cancer trials (e.g. time to progression
(TTP)). One reason may be that secondary endpoints
are not powered or there is a clinical rationale that the
secondary outcome cannot be expected to yield effects
similar to primary endpoints. In a similar vein, effect
sizes should not be expected to be uniform across
HRQoL domains for demonstrating treatment benefit
because some smaller effect sizes (e.g. < 10 points) may
be important. In this research we attempt to show that
some small effect sizes on a MD scale might be dis-
missed as clinically irrelevant but remain important on a
relative scale.
Little attention has been given to smaller HRQoL
effects (MDs) which are often glossed over unless a
‘statistically significant’ p-value is reported alongside.
Small MDs tend to be perceived as offering limited
HRQoL benefit but can mask important improve-
ments, particularly when data are analysed using an
alternative scale (e.g. OR scale). This presents a chal-
lenge for setting thresholds for defining clinically rele-
vant HRQoL effect sizes. Moreover, ORs can facilitate
an interpretation of effects similar to hazard ratios
(HR), familiar to many oncologists (OR are interpreted in
a similar way to HRs).
Therefore, in this article after presenting baseline char-
acteristics, we offer effect size categories based on the
OR and describe example situations of the relationship
between ORs and MDs. We discuss aspects of statistical
significance of small effects in the context of ORs and
MDs and compare preferences between ORs vs MDs
from several clinicians; Finally, we compare ORs and
MDs with time a to deterioration (TD) approach (TD ≥5
points) following Anota [13].
Methods
Data
HRQoL data from six randomized controlled trials
(RCT) conducted by the CRUK & UCL CTC were ana-
layzed [9, 18–22]. These were selected because they
comprised of all patient level QLQ-C30 data available in
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the CTC database from RCTs in lung cancer which had
been published.
(i) ‘TOPICAL’: A phase III trial in NSCLC patients
unfit for chemotherapy comparing erlotinib with
placebo [18]; N = 670 patients.
(ii)‘SOCCAR’: A phase II trial comparing concurrent
vs. sequential chemotherapy in NSCLC patients
[19]; N = 130.
(iii) ‘Study 10’: A phase II trial comparing Gemcitabine/
Carboplatin versus Cisplatin/Etoposide in patients
with small cell lung cancer (SCLC) [20]; N = 241.
(iv) ‘Study 11’: A phase III trial comparing
Gemcitabine/Carboplatin versus Mitomycin/
Ifosfamide /Cisplatin in patients with stage IIIB or
IV NSCLC [9]; N = 422
(v) ‘Study 12’: A phase III trial comparing Thalidomide
combined with chemotherapy versus chemotherapy
alone in SCLC patients [21]; N = 724
(vi)Study 14: A phase III trial comparing Thalidomide/
Gemcitabine/Carboplatin versus Gemcitabine/
Carboplatin alone in NSCLC patients [22]; N = 722
Assessments
Data were collected during clinic visits and question-
naires returned by patients during follow up; QLQ-C30
was assessed at several time points including baseline,
pre and post chemotherapy and at monthly intervals for
at least 24 months or until disease progression.
Statistical analysis
Patient level HRQoL scores for each of the 15 domain
scores were analysed using a a repeated measures [21, 22]
analysis for reporting MDs and a more novel Beta
Binomial (BB) model in a mixed model framework [23]
for reporting ORs. For the BB model, responses were
transformed to a (0,1) scale using the transformation [23]
Y-a/b-a, where a and b are the minimum and maximum
possible scores and Y the observed response. For example,
a score of 80 is transformed as 80- 0/(100-a) = 80/100 =
0.8. Dichotomization is not required for a BB model to
generate ORs.
The BB model has been used in a variety of applica-
tions [23–25]. Its advantages over standard (linear)
models in terms of statistical properties are widely re-
ported [25, 26]. The BB is also flexible because it models
scores at the extreme ends of the scale (e.g. many pa-
tients scoring 0 or 100), a common feature of QLQ-C30
scores, using zero–one inflated model [25, 26]. MDs
were classified similar to those described by Cocks [7];
‘Trivial’ (0–3 points), ‘Small’ (3–10 points), ‘Modest’/
‘Medium’ (10–15 points) and ‘Large’ (>15 points). Simi-
larly, ORs were classified as 1 ± 0.05 (‘Trivial’), 1 ± 0.1
(‘Small’), 1 ± 0.2 (‘Medium’) and <0.8 or >1.2 (‘Large’).
Time to Deterioration (TD) was determined using the
first time where scores reduced/increased by ≥ 5 points.
Patients without deterioration were censored. A Kaplan-
Meier and Cox proportional hazards (PH) analysis was
carried out.
A pilot survey was carried out to determine preliminary
evidence of whether clinicians and/or patients preferred
ORs or MDs for expressing treatment effects. Three items,
physical function (PF), Pain (PA) and cognitive function
(CF) from the 15 domains were randomly selected and
presented to each of five clinicians and their patients
(where possible). Patients/clinicians were asked to state
preferences for ORs or MDs (Additional file 1). Lower/
High scores express preferences for ORs; scores close to 5
express indifference.
Results
Demographics and baseline characteristics
The median age was 64 years (range 27–86 years) with old-
est patients in the TOPICAL trial (median age 77); 61 %
were male; 67 % were ECOG (0–1), 24 % ECOG 2 and 9 %
ECOG 3 (Table 1); less than half were stage IIIa-IIIb (47 %)
[9, 18–22]. Most QLQ-C30 responses were >90 %
complete at baseline (Additional file 2: Table S1) with the
exception of study 10 (about 60 % complete). More than
50 % of data were available for at least 5 time points.
Distribution of QLQ-C30
Most (>85 %) QLQ-C30 responses were very skewed
(Fig. 1 & Additional file 2: Figure S1). For TOPICAL,
14/15 (93 %) of scores had alpha or beta values (special
values associated with a BB distribution relating to the
mean and variance) <1; Kolmogorov-Smirnov tests
rejected normality (p-value <0.001). Therefore, using the
mean as a measure of HRQoL benefit and consequently
MDs is not considered a suitable reporting metric for
HRQoL scores. Statistical analysis should be conducted
according to the underlying (true) distribution of the
data. The distribution of QLQ-C30 scores from the
six trials were not normally distributed in most
(≥85 %) of cases.
Relationship between MDs and ORs
Few 4/90 (4 %) HRQoL treatment effects (MDs) were
‘Large’ (>15 points) or ‘Medium’ (10–15 points); 27/90
(30 %) were ‘Small’ (3–10 points) and 59/90 (66 %)
‘Trivial’ (0–3 points) MDs; For ORs, 22/90 (24 %) were
‘Large’ (effects > 20 %) or ‘Medium’ (effects between
10 % to 20 %) with the rest being ‘Small’ or ‘Trivial
(10 % and 5 % respectively). ORs were therefore more
than seven times more likely to detect larger differences
which can yield up to 20 % improvements in HRQoL
([0.24/0.76]/[0.04/0.96]) compared with MDs (Tables 2
and 3).
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Additional file 2: Figure S2 shows the relationship be-
tween MDs and ORs and shows general agreement in
terms of the direction of effects (i.e. observations in the
upper right quadrant are ORs >1 and MDs >0; estimates
in the lower left are ORs < 1 and MDs <0).
Four examples are provided to understand the rela-
tionship between ORs and MDs.
Example 1: when MDs are small but ORs are large
In the TOPICAL Trial the MD for constipation (CO)
symptoms were 2.6 points (p = 0.1314) while this was an
OR of 1.17 (p < 0.0001) – the choice of interpretation is
‘a worsening in CO by a mean difference of 2.6 points
with erlotinib compared to placebo’ vs ‘patients are 17 %
more likely of having worsening CO symptoms with er-
lotinib compared to placebo’. The MD scale gives the
impression that CO symptoms worsens by a ‘Trivial’
amount of 2.6 points (Table 2). This tends to occur
when responses are skewed (Fig. 1 and Additional file 2:
Figures S1, S2 and S3). In the presence of heavily skewed
data, the OR is a suitable choice for presenting HRQoL
effects from the QLQ-C30.
Example 2: when MDs are ‘Large’ but ORs are ‘Medium’
or ‘Small’
In the TOPICAL trial, patients had worse diarrhoea (DI)
with erlotinib: MD of 15.1 (‘Large’ effect) points (p <0.001)
with a corresponding OR of 1.12 (p = 0.0505). The DI
scores were considerably skewed (Fig. 1) which might ex-
plain why the larger MD corresponded with only 12 %
(‘Medium’ effect) higher odds of diarrhoea with erlotinib
compared to placebo (OR = 1.12). The OR appears to have
modified the ‘Large’ effect size (borderline significance) to
a smaller (non-significant) effect size.
Example 3: when MDs are ‘Medium’ but ORs are ‘Large’
In study 10, RF improved by a MD of about 13 points
(Table 2) with the experimental treatment – a ‘Medium’
effect. Using an OR, this was an improvement in role
function by almost 30 % (OR =1.29 ‘). On examination
of Additional file 2: Figure S1, responses fell into only
three distinct categories at 0, 50 and 100 and scores
were not Normally distributed making use of the MD
questionable. The OR approach has relegated a ‘Medium’
effect to a ‘Large’ effect.
Example 4: when MDs and ‘ORs agree on the direction of
effects
In the TOPICAL trial, two of the MDs (MD of 3.2 and
3.6 in TOPICAL; p-values of 0.0017 and 0.0007 for PF
and CF respectively) had corresponding ORs of 1.10 and
1.14 (p-value = 0.0168 and 0.0107). Both MDs and ORs
are in agreement that PF and CF are improving with the
experimental treatment. Hence, on average, patients
had 10 % and 14 % higher odds of improved PF and CF
on erlotinib compared with placebo respectively
(Table 2).
The above are a limited number of examples reflect-
ing the challenges associated with defining thresholds
of HRQoL differences with the MD. Another issue that
can complicate interpretation is when small effects be-
come difficult to interpret and justification is made
through statistical significance. Statistical significance
of small HRQoL effects are often reported, but the
clinical relevance not always discussed. Table 3 shows
that 28/90 (31 %) of ‘small’ or ‘Trivial’ effects based on
MD were statistically significant compared with 7/90
(8 %) for ORs.
Table 1 Summary of baseline characteristics for each trial
TOPICAL (N = 670) SOCCAR (N = 130) Study 10 (N = 241) Study 11 (N = 422) Study 12 (N = 724) Study 14 (N = 722)
Age (Median, range) 77 (72–82) 62 (39–75) 62 (27–81) 62 (34–81) 65 (38–86) 62 (33–84)
Gender:
Male 409 (61 %) 79 (61 %) 136 (56 %) 296 (70 %) 412 (57 %) 465 (64 %)
Female 261 (39 %) 51 (39 %) 105 (43 %) 126 (30 %) 312 (43 %) 257 (36 %)
ECOG: 0–1 106 (16 %) 130 (100 %) 164 (68 %) 365 (86 %) 529 (73 %) 648 (90 %)
2 372 (56 %) 0 60 (25 %) 48 (11 %) 153 (21 %) 74 (10 %)
3 192 (29 %) 0 17 (7 %) 9 (21 %) 42 ( 6 %) 0
Stage: IIIa-IIIb 234 (35 %) 130 (100 %) 103 (43 %) 200 (47 %) 368a(51 %) 322 (45 %)
IV 436 (65 %) 0 138 (57 %) 222 (53 % 356a(49 %) 400 (55 %)
alimited disease n = 368, extensive disease n = 356
Eastern Co-operative Oncology Group (ECOG) status:
0: Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50 % of waking hours
3 Capable of only limited self-care, confined to bed or chair more than 50 % of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
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Fig. 1 Distribution of QLQ-C30 responses: TOPICAL (x-axis is QLQ-C30 score on a scale of 0 to 1 and - y axis is relative frequency)
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Table 2 Mean differences compared with odds ratios
Odds ratio Mean Difference (MD)
Study QLQ-C30 Odds Ratio Lower 95 % CI Upper 95 % CI P-value Difference Lower 95 % CI Upper 95 % CI P-value
TOPICAL QL 0.99840 0.92173 1.08145 0.4687 0.6433 −1.4409 2.7274 0.5450
(N = 670) PF 1.10396 1.01803 1.19714 0.0168 3.2075 1.2060 5.2090 0.0017
SF 1.00312 0.90378 1.11339 0.4932 0.9528 −2.0474 3.9529 0.5334
RF 1.07206 0.96858 1.18660 0.1790 2.2751 −0.8554 5.4055 0.1542
EF 1.13356 1.02036 1.25931 0.0196 2.3352 −0.2060 4.8763 0.0717
CF 1.14062 1.03104 1.26184 0.0107 3.6824 1.5497 5.8152 0.0007
FA 0.97062 0.88076 1.06965 0.5472 0.4928 −2.0393 3.0249 0.7027
NV 1.03299 0.90587 1.17796 0.6279 2.0823 0.2119 3.9527 0.0291
PA 0.84858 0.75492 0.95386 0.0060 −4.1552 −6.7318 −1.5786 0.0016
DY 0.90265 0.83349 0.97755 0.0118 −6.9802 −9.8067 −4.1538 <.0001
SL 1.06142 0.96736 1.16463 0.2078 −0.5849 −3.4526 2.2829 0.6892
AP 1.14413 1.04285 1.25524 0.0044 7.7375 4.3808 11.0943 <.0001
CO 0.94016 0.85740 1.03090 0.1892 −9.3181 −11.9276 −6.7085 <.0001
DI 1.11676 0.99977 1.24744 0.0505 15.0773 12.5221 17.6324 <.0001
FI 1.06304 0.94126 1.20057 0.3245 −3.9678 −5.8688 −2.0668 <.0001
SOCCAR QL 1.05911 0.94600 1.18576 0.3186 −0.3363 −3.2927 2.6201 0.8234
(N = 130) PF 1.00632 0.88085 1.14967 0.5260 −0.7855 −3.5393 1.9684 0.5758
SF 1.07805 0.94331 1.23204 0.2696 −0.1569 −3.8385 3.5246 0.9333
RF 0.92530 0.81065 1.05617 0.2497 −1.2639 −5.1956 2.6679 0.5283
EF 0.86964 0.74753 1.01171 0.0704 −0.4552 −3.7208 2.8104 0.7845
CF 1.21469 1.04469 1.41237 0.0115 2.8249 0.2230 5.4268 0.0334
FA 1.09003 0.96258 1.23436 0.1740 −3.2001 −6.5586 0.1585 0.0618
NV 0.96687 0.81577 1.14595 0.4073 1.1136 −1.6169 3.8441 0.4237
PA 0.93405 0.81386 1.07199 0.3313 −3.3510 −6.7785 0.07654 0.0553
DY 0.90277 0.81740 0.99707 0.0436 −2.0557 −5.5569 1.4456 0.2495
SL 1.07573 0.95694 1.20927 0.2211 −0.8873 −4.4778 2.7033 0.6278
AP 0.94817 0.83543 1.07613 0.4095 −0.2265 −4.0527 3.5997 0.9075
CO 1.10100 0.95927 1.26368 0.1709 −0.8742 −4.4752 2.7267 0.6339
DI 0.84506 0.68652 1.04021 0.1121 −0.4002 −2.8583 2.0580 0.7494
FI 1.10633 0.94859 1.29029 0.1977 1.1951 −2.1001 4.4903 0.4768
Study 10 QL 0.94126 0.84476 1.05135 0.3912 −1.6241 −4.1816 1.8922 0.6124
(N = 241) PF 1.00563 0.89071 1.13537 0.9276 2.8207 −1.9594 7.6007 0.2467
SF 1.00006 0.88002 1.13647 0.9993 4.0507 −0.9736 9.0750 0.1139
RF 1.28860 1.08877 1.50121 0.0084 13.0540 0.3211 25.7870 0.0445
EF 1.07878 0.93850 1.24003 0.2156 −2.8502 −7.4563 1.7558 0.2248
CF 1.14441 0.96173 1.29133 0.1494 5.6888 2.0359 9.3417 0.0023
FA 0.87034 0.77408 0.97858 0.0203 −2.0359 −6.1599 2.0882 0.3327
NV 1.10180 0.94137 1.28957 0.2269 0.7394 −2.9807 4.4594 0.6965
PA 0.81452 0.70091 0.94655 0.0075 −0.9057 −5.0882 3.2768 0.6708
DY 0.90282 0.82439 0.98871 0.0275 −6.8389 −11.3035 −2.3743 0.0027
SL 0.95514 0.85447 1.06767 0.4188 −0.3213 −5.8080 5.1655 0.9085
AP 1.08583 0.95447 1.23526 0.2104 2.2718 −2.6561 7.1997 0.3657
CO 0.86569 0.75412 0.99376 0.0405 −2.6788 −7.7010 2.3433 0.2953
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Table 2 Mean differences compared with odds ratios (Continued)
DI 0.92437 0.77487 1.10271 0.3818 −3.4211 −6.4418 −0.4004 0.0265
FI 1.06566 0.82875 1.27688 0.3624 2.1354 −2.1141 6.5714 0.3252
Study 11 QL 0.95236 0.89286 1.09135 0.5552 −2.3613 −5.1511 2.9822 0.7334
(N = 422) PF 0.93089 0.84991 1.01958 0.1229 −2.7725 −6.0805 0.5356 0.1003
SF 0.96121 0.87398 1.05714 0.4147 −3.3172 −6.9318 0.2974 0.0720
RF 1.08853 0.94125 1.23477 0.3324 −7.1287 −14.3603 0.1028 0.0533
EF 0.97549 0.88043 1.08081 0.6350 −4.8538 −8.0029 −1.7047 0.0026
CF 0.95256 0.85588 1.06016 0.3731 −0.6141 −3.1705 1.9422 0.6374
FA 1.10834 1.00731 1.21950 0.0349 3.3375 0.2209 6.4541 0.0359
NV 1.29384 1.15215 1.42351 <0.0001 5.4863 3.3832 7.5895 <.0001
PA 1.00011 0.89283 1.12028 0.9985 0.9084 −1.9043 3.7210 0.5264
DY 1.04262 0.96229 1.12965 0.3073 −1.6110 −5.1973 1.9754 0.3783
SL 1.02938 0.94433 1.12209 0.5102 −4.0055 −7.6480 −0.3629 0.0312
AP 1.04393 0.94403 1.15440 0.4019 4.6020 0.7884 8.4157 0.0181
CO 1.06104 0.95671 1.17675 0.1117 2.6096 −0.7817 6.0008 0.1314
DI 1.13002 0.95487 1.33729 0.1547 0.9181 −0.9858 2.8219 0.3442
FI 1.08816 0.92995 1.22408 0.4498 1.9684 −2.0451 5.6714 0.5022
Study 12 QL 0.96311 0.89103 1.04421 0.5034 −0.8545 −2.8925 1.19985 0.3214
(N = 724) PF 1.00156 0.93624 1.07143 0.9639 −0.01443 −2.9124 2.8835 0.9922
SF 0.93058 0.87602 0.98855 0.0196 0.2535 −2.2932 2.8002 0.8453
RF 0.94478 0.89925 0.99755 0.0536 −6.3209 −11.8670 −0.7747 0.0255
EF 0.96366 0.90173 1.02985 0.2747 −4.0689 −6.3917 −1.7461 0.0006
CF 0.96082 0.89968 1.02612 0.1334 −1.2498 −3.1386 0.6391 0.1946
FA 0.99963 0.94240 1.06033 0.4901 −0.6901 −2.8719 1.4917 0.5352
NV 0.95818 0.88480 1.03765 0.2933 5.4863 3.3832 7.5895 <.0001
PA 0.96961 0.89701 1.04809 0.4370 0.9084 −1.9043 3.7210 0.5264
DY 1.03922 0.98989 1.09102 0.1210 3.9991 1.3876 6.6105 0.0027
SL 0.90162 0.84630 0.96055 0.0014 −15.5470 −18.0563 −13.0378 <.0001
AP 1.06787 0.99510 1.14597 0.0682 −2.2811 −4.6592 0.09705 0.0601
CO 1.16848 1.09944 1.24186 <.0001 2.6096 −0.7817 6.0008 0.1314
DI 1.05255 0.95709 1.15754 0.2909 −2.3379 −3.8004 −0.8754 0.0017
FI 1.01842 0.92606 1.12000 0.7064 1.6197 −2.5375 5.7768 0.4445
Study 14 QL 0.96684 0.91236 1.05549 0.2123 −1.3897 −3.2450 0.9808 0.0983
(N = 722) PF 0.95134 0.89346 1.01298 0.1193 −1.7843 −3.6934 0.1248 0.0670
SF 1.01050 0.94612 1.07926 0.7557 0.8731 −1.1044 2.8507 0.3867
RF 0.92540 0.89452 0.99358 0.0412 −6.0800 −10.1493 −2.0107 0.0034
EF 0.89881 0.83696 0.96523 0.0034 −1.9677 −3.5103 −0.4251 0.0124
CF 1.04520 0.96868 1.12776 0.2543 −0.07931 −1.4565 1.2978 0.9101
FA 1.03864 0.97432 1.10720 0.2450 1.1338 −0.5280 2.7955 0.1811
NV 0.92440 0.84363 1.01291 0.0920 −1.7769 −3.0100 −0.5437 0.0048
PA 1.07278 0.98702 1.16600 0.0984 −0.5521 −2.2252 1.1210 0.5176
DY 1.02074 0.96756 1.07683 0.4520 1.3292 −0.5879 3.2464 0.1741
SL 0.96340 0.89862 1.03286 0.2937 −8.0830 −10.1365 −6.0295 <.0001
AP 0.98802 0.91442 1.06755 0.7602 −3.8491 −5.8767 −1.8216 0.0002
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Example 5: Potentially unreliable statistically significant
conclusions using MD
In study 12, for Diarrhoea, the MD was −2.3 (p = 0.0017).
The corresponding OR was 1.05 (p = 0.2909). The clinical
relevance of the small improvement in DI symptoms with
experimental treatment might be difficult to judge. On the
ORs scale, DI is actually shown to be worse: a 5 % likeli-
hood of worsening diarrhoea (a common side effect with
this chemotherapy) on the experimental treatment. Exam-
ination of Additional file 2: Figure S2 shows heavily
skewed DI scores – with about 15 % of patients showing
worsening DI symptoms. The choice of a mean statistic
here is likely to lead to an unreliable or unexpected statis-
tical conclusion. Further examples of differing statistical
conclusions between ORs and MDs are shown in
Additional file 2: Tables S2, S3.
Effect size classification for ORs and MDs
Estimates for OR effect size categories similar to
those described earlier [7] were determined using a
cumulative frequency plots from MDs and ORs (Fig. 2
and Additional file 2: Tables S2, S3, S4). Effect sizes in
terms of ORs were broadly classified as: ‘Trivial’: ORs
within ±5 % of 1 (i.e. ORs between 0.95 and 1.05); ‘Small’
effects (ORs 1.05 -1.10 or 0.90 – 0.95); ‘Medium effects
(ORs 1.10 – 1.20 or 0.80-0.90) and ‘Large’ effects ORs
either >1.20 or <0.80. Additional file 2: Table S4 shows
that 12/59 (20 %) of ‘Trivial’ effects based on MDs might
be clinically important because on an OR scale these were
‘Medium’ or ‘Large’. Consequently some clinically import-
ant effects may be missed using MDs.
Figure 2 shows median HRQoL effect sizes are 2.5
points (half of effect sizes are ≤2.5), roughly equivalent
to 7 % changes in HRQoL on the OR scale; similarly for
the lower and upper quartiles, 25 % of effect sizes ≤1
point or 4 % changes on the OR scale; and 75 % of effect
sizes are ≤3.6 points (ORs of about 1.10).
Secondly, for effect sizes of 1, 3, 5 10 and >15
points, the equivalent ORs are about 1.02, 1.07, 1.13,
1.25 and 1.37 respectively. The threshold for a large
effect size of >15 points is challenging: patients ex-
pected to improve/worsen by almost 40 %. This may
be a difficult target for some cancer drugs to achieve
when compared with each other.
Summary of preference scores from survey
Five lung cancer clinicians completed a pilot (Additional
file 1) survey (London UCH, Liverpool, Leeds, Chester
and Imperial College London). At this time no patient
responses were available. Hence a total of 15 scores from
5 clinicians who expressed preferences for either ORs or
MDs for each of PF, Pain and CF were analysed. Stron-
ger preferences were expressed for ORs over MDs: mean
scores of 2.4, 3.1 and 2.8 for PF, Pain and CF respect-
ively. Hence, initial evidence suggests clinician prefer-
ence was greater for ORs than MDs. The results would
need to be confirmed in a larger sample.
Comparison with time to deterioration
The time it takes for a patient to deteriorate from base-
line by ≥5 was not possible for about 13 % HRQoL do-
main scores due to too few events (i.e. patients did not
show of ≥5 points). Moreover, a TD of ≥5 points was not
always possible because scores were clustered in values
such as 16.7, 33.3 and 66.6 (e.g. as in CF scores for TOP-
ICAL -Fig. 1). No patient experienced (or could experi-
ence) a TD of exactly 5, 10 or 15 points (the possible
values of the QLQ-C30 for CF were only 0, 16.7, 33.3,
50.0, 66.7, 83.3 and 100). The median TD (Additional
file 2: Table S5) was not calculable for some symptom
Table 2 Mean differences compared with odds ratios (Continued)
CO 1.07744 1.00746 1.15228 0.0295 10.9195 8.8799 12.9590 <.0001
DI 1.05388 0.95077 1.16817 0.3177 −1.6529 −2.8431 −0.4628 0.0065
FI 0.99605 0.89553 1.10785 0.9418 2.3020 −2.4081 7.0122 0.3375
Key: 5 functional scales: PF physical function, RF role function, EF emotional function, CF cognitive function, and SF social functioning; 9 ‘symptom’ scales: FA
fatigue, NV nausea & vomiting, PA pain, DY dyspnoea, IN insomnia, AL appetite loss, CO constipation, DI diarrhoea, FI financial problems; and QL a global health
status score
Positive differences on the functional scale are improvements in quality of life with the experimental arm
Positive differences on the symptom scale suggests a worsening in quality of life with the experimental arm
Table 3 Magnitude of effect sizes
All Stat. siga
Mean Difference n (%) n (%)
Trivial: 0–3 points 59 (66 %) 6 (19 %)
Small: 3 to 7 points 27 (30 %) 22 (69 %)
Medium: 10 to 15 points 2 (2 %) 2 (6 %)
Large: >15 points 2 (2 %) 2 (6 %)
Total 90 32
Odds ratio
0.95 – 1.05 or 1.0 – 1.05 35 (39 %) 0
0.90 – 0.95 or 1.05 – 1.10 33 (37 %) 7 (33 %)
0.80 – 0.90 or 1.10 – 1.20 19 (21 %) 11 (52 %)
<0.80 or > 1.20 3 (3 %) 3 (14 %)
Total 90 31
aMDs or ORs statistically significant at the 5 % level
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and function scores: for CF, a HR of 1.05 (p = 0.241) was
reported: patients had a 5 % increased risk of deteriorat-
ing (≥5 point reduction) CF with erlotinib compared to
placebo. The OR of 1.14 and MD of 3.2 in contrast show
improvements in CF. The definition of deterioration is
therefore critical for a valid estimate to be possible.
When the TD for CF was changed to ≥16 points (‘Large’
effect), the medians become calculable as 77 vs 87 months
for erlotinib vs placebo (HR = 0.92; p = 0.56): the risk of
deterioration in CF was slightly worse (by 8 %) with erloti-
nib compared to placebo. The Kaplan Meier curves cross
and the PH assumption was violated, a complication the
OR analysis avoids.
Conclusion
An alternative metric to the commonly reported MD
was presented in the form of ORs. Skewness of QLQ-
C30 scores might render statistical and clinical inter-
pretation of MDs questionable. Alternative effect size
categories for ORs were proposed. We have also
shown a relationship between ORs and MDs for
QLQ-C30 measures; ORs can on the one hand reveal
important HRQoL effects which might otherwise be
missed with MDs, particularly those perceived to be
‘Trivial’ or ‘Small’. Conversely, effect sizes based on
MDs thought to be ‘Medium’ or ‘Large’ may appear
less exaggerated with ORs; Treatment effects from
Fig. 2 Cumulative Frequency Plot of Effect Sizes for MDs and ORs. Horizontal reference lines are MDs effect sizes of 3, 10 and 15 points; circles
refer to ORs and squares refer to MDs
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TD type analyses did not always result in estimates of
effect sizes and interpretations were complicated by
non PH assumptions. Finally we showed results from
a pilot survey which suggest oncologists may prefer
ORs over MDs for interpreting QLQ-C30 effects.
The use of the ORs has been used previously in
HRQoL data. Feddern et al. (2015) [27] reports them for
assessment of pain; Chie et al. (2015) [28] uses a propen-
sity score (logistic regression) approach to report odds
of HRQoL deterioration; Kurita et al. (2015) [29] use
ORs with the QLQ-C30 in renally impaired patients. In
these analyses scores were dichotomized in order to gen-
erate the ORs. In our analysis, no such dichotomization
(and consequent loss of information) was required due
to flexibility of the Beta-Binomial regression approach.
Patient and clinician understanding of MDs have not
been previously shown to be concordant [7] and this may
in part be due to how HRQoL benefits are expressed to
patients. Clinicians and patients may find it easier to agree
on relative quantities than absolute differences. The pilot
survey results may support relative quantities. The choice
between interpretations such as: “your diarrhoea will be
worse with the new treatment by 15 points, on average”
instead of: “the likelihood of diarrhoea with the new treat-
ment is significantly higher by about 11 % compared to
placebo”, is a matter of preference, but the latter may be
appealing for some. Aligning understanding of smaller
effect sizes is increasingly important with the emergence
of novel treatments for lung cancer being compared with
each other (and not just placebo).
There are several advantages and disadvantages of both
MDs and ORs. First, ORs evaluate relative (instead of ab-
solute) treatment effects. For objective endpoints, absolute
differences (e.g. 4 vs 3 months survival) may provide easier
interpretations of treatment benefits (although the effects
are median and not mean differences in cancer trials).
However, HRQoL are self-reported endpoints for which
even the most experienced clinician has difficulty inter-
preting. For such endpoints, a relative scale may be more
useful. If treatment effects from primary endpoints are
judged by relative quantities (e.g. hazard ratios), there are
no reasons why treatment effects from HRQoL endpoints
should not also be assessed this way. Both survival time
and HRQoL share some similar distributional properties
(e.g. skewed or censored). There is some concern that
effects near the boundaries (floor/ceiling) will be overva-
lued with ORs compared to effects around the middle.
However, such concerns can be addressed through the use
of zero–one inflated models (Khan, 2014) [25] which
model the over/under dispersion.
Secondly, the OR model assumes a fixed odds ratio
over time (i.e. the effect is constant over time), which
may not hold in a longitudinal QoL setting. Reliable in-
terpretation of MDs also depends on an absence of
treatment by time interactions (i.e. ORs and MDs are
not dependent on specific time points). Thirdly, statis-
tical models for MDs will provide predicted patient level
HRQoL responses. For example, a patient taking experi-
mental treatment with a certain demographic profile
might yield a predicted PF score (e.g. 5 points). Similarly,
a model for estimating ORs can be used to predicted a
probability of a achieving a specific PF score for a given
patient (group of patients) on the experimental treat-
ment (response curves are advocated by the FDA for pa-
tient reported outcomes) [30].
The suggested effect size of >10 units on the QLQ-C30
was proposed almost two decades ago when fewer treat-
ment comparators were available [15]. Few (about 2 %)
MDs were >10 points and this research confirms earlier
conclusions that small changes in HRQoL can be import-
ant (Cella, 2002) [7, 31]. Importantly, the implications of
skewed distributions were not factored in when the mag-
nitude of effect sizes were defined in earlier research.
There are several strengths and limitations of this
analysis. First, a large sample size is used from clinical
trials in similar groups of patients. Secondly, established
criteria for classifying effect sizes were used for MDs
[7]. Third, the BB model is a robust approach to analys-
ing skewed data with ceiling effects, without arbitrary
dichotomisation of responses. Finally, interpreting ORs
is similar to that of HRs which many oncologists are
familiar with.
Although the BB approach offers an alternative
approach to analyse and interpret HRQoL effects, it is
more complex. The complexity is outweighed by the
benefits of reliable and potentially easier to interpret
estimates of effect. A further limitation is that analysis
has been restricted to lung cancer patients, but can be
applied to other tumour types and disease areas. The
classifications suggested for ORs in this analysis are
arbitrary (even if based on the observed data) and differ-
ent results can occur with alternative categories. Defin-
ition of effect sizes may require some threshold to be
set which may necessarily be subjective. However, a
starting point in our view is that the most appropriate
metric is used to present HRQoL effects in cancer
patients, an area for further research. The initial survey
results too should also be confirmed in a larger sample
size.
Treatment effects for HRQoL from the QLQ-C30
should be reported using relative quantities such as ORs
which appear to be clinically intuitive, easier to interpret
and where analysis involves modelling the skewed distri-
bution of responses.
Highlights
The highlights of this paper are:
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 Mean differences in HRQoL are difficult to interpret
for clinicians and patients alike, especially when the
difference is small.
 An alternative measure to reporting and interpreting
HRQoL treatment differences using a relative
quantity such as an odds ratio can greatly facilitate
patient –clinician understanding of a ‘relevant’
HRQoL improvement.
 We offer a way in which mean differences in
HRQoL can be interpreted as approximate odds
ratios. Effect sizes are categorized as ‘Trivial, ‘Small’
‘Medium’ and ‘Large’ for odds ratios in a similar way
to mean differences
 Although the BB approach offers an alternative
approach to analyse and interpret HRQoL effects, it
is more complex. The complexity is outweighed by
the benefits of reliable and potentially easier to
interpret estimates of effect.
 Our approach will allow patients and clinicians to
align their understanding of treatment benefits using
HRQoL outcomes.
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